JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2002; 39:1780-1786
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horwich, T. B.
Right arrow Articles by Borenstein, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horwich, T. B.
Right arrow Articles by Borenstein, J.

Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure

Tamara B. Horwich, MD*, Gregg C. Fonarow, MD, FACC{dagger},*, Michele A. Hamilton, MD, FACC{dagger}, W. Robb MacLellan, MD, FACC{dagger} and Jeff Borenstein, MD{ddagger}

* Department of Medicine, University of California, Los Angeles, USA
{dagger} Ahmanson–University of California Cardiomyopathy Center, Los Angeles, USA
{ddagger} Cedars–Sinai Health System, Los Angeles, California, USA



View larger version (17K):

[in a new window]
 
Figure 1 Kaplan-Meier survival analysis for the entire cohort by quartile of hemoglobin (Hb) level.

 


View larger version (17K):

[in a new window]
 
Figure 2 Mortality for the entire cohort by decile of hemoglobin level.

 


View larger version (41K):

[in a new window]
 
Figure 3 Mortality by hemoglobin quartile (Q) for the total cohort compared to subgroups of men (Q1 <12.6; Q2 12.6–13.9; Q3 14.0–15.0; Q4 >15.0 g/dl) and women (Q1 <11.6; Q2 11.6–12.6; Q3 12.7–13.8; Q4 >13.8 g/dl), patients with ischemic and nonischemic cardiomyopathy (CMY), and excluding patients who underwent urgent or elective status transplantation.

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2002 by the American College of Cardiology Foundation.